Cytokinetics Inc (CYTK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.82B
Last updated: Nov 17, 2026 at 11:04 AM ET
Cytokinetics Inc (CYTK) Earnings: Report Dates and Results
Cytokinetics (CYTK) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Cytokinetics reported EPS of -$1.37, above the -$1.50 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CYTK has an expected report date of Feb 22, 2027.
CYTK Earnings Call
The latest CYTK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CYTK beat 13, missed 24 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $47.56M, up 2351.5% from $1.94M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.37 | -$1.50 | -$1.65 - -$1.10 | +8.67% | Beat | N/A | 18 | 2 up, 0 down | Nov 4, 2026 | $47.56M |
| Jun 30, 2026 | -$1.50 | -$1.63 | -$2.02 - -$1.26 | +7.98% | Beat | N/A | 15 | 9 up, 3 down | Aug 6, 2026 | $28.62M |
| Mar 31, 2026 | -$1.67 | -$1.65 | -$1.79 - -$1.37 | -1.21% | Miss | N/A | 13 | 0 up, 1 down | May 5, 2026 | $19.36M |
| Dec 31, 2025 | -$1.50 | -$1.56 | -$1.77 - -$0.20 | +3.85% | Beat | N/A | 9 | 1 up, 2 down | Feb 24, 2026 | $17.75M |
| Sep 30, 2025 | -$1.54 | -$1.59 | -$2.55 - -$1.29 | +3.14% | Beat | N/A | 14 | 3 up, 0 down | Nov 5, 2025 | $1.94M |
| Jun 30, 2025 | -$1.12 | -$1.34 | -$1.54 - -$0.35 | +16.42% | Beat | N/A | 17 | 0 up, 1 down | Aug 7, 2025 | $66.77M |
| Mar 31, 2025 | -$1.36 | -$1.36 | -$1.59 - -$1.17 | 0.00% | In line | N/A | 15 | 2 up, 2 down | May 6, 2025 | $1.58M |
| Dec 31, 2024 | -$1.26 | -$1.17 | -$1.52 - -$0.30 | -7.33% | Miss | N/A | 16 | 0 up, 0 down | Feb 27, 2025 | $17.18M |
| Sep 30, 2024 | -$1.36 | -$1.24 | -$1.46 - -$1.09 | -9.68% | Miss | N/A | 16 | 1 up, 0 down | Nov 6, 2024 | $463000 |
| Jun 30, 2024 | -$1.31 | -$0.91 | -$1.38 - -$0.61 | -43.96% | Miss | N/A | 16 | 0 up, 0 down | Aug 8, 2024 | N/A |
| Mar 31, 2024 | -$1.33 | -$1.17 | -$1.35 - -$0.89 | -13.68% | Miss | N/A | 15 | 2 up, 0 down | May 8, 2024 | $835000 |
| Dec 31, 2023 | -$1.38 | -$0.97 | -$1.47 - -$0.38 | -42.27% | Miss | N/A | 17 | 0 up, 0 down | Feb 27, 2024 | $1.67M |
| Sep 30, 2023 | -$1.35 | -$0.76 | -$1.11 - -$0.40 | -77.63% | Miss | N/A | 15 | 1 up, 0 down | Nov 2, 2023 | $378000 |
| Jun 30, 2023 | -$1.34 | -$1.24 | -$1.43 - -$0.31 | -8.06% | Miss | N/A | 13 | 0 up, 0 down | Aug 3, 2023 | $867000 |
| Mar 31, 2023 | -$1.38 | -$1.18 | -$1.41 - -$1.03 | -16.95% | Miss | N/A | 13 | 1 up, 0 down | May 4, 2023 | $4.61M |
| Dec 31, 2022 | -$1.45 | -$1.21 | -$1.39 - -$0.97 | -19.83% | Miss | N/A | 15 | 0 up, 0 down | Mar 1, 2023 | $1.96M |
| Sep 30, 2022 | -$1.28 | -$1.17 | -$1.28 - -$1.06 | -9.40% | Miss | N/A | 13 | 0 up, 0 down | Nov 3, 2022 | $2.52M |
| Jun 30, 2022 | -$0.23 | -$1.01 | -$1.10 - -$0.95 | +77.23% | Beat | N/A | 10 | 0 up, 0 down | Aug 4, 2022 | $88.97M |
| Mar 31, 2022 | -$1.02 | -$0.94 | -$1.04 - -$0.75 | -8.51% | Miss | N/A | 11 | 0 up, 0 down | May 4, 2022 | $1.15M |
| Dec 31, 2021 | -$0.36 | -$0.84 | -$1.00 - -$0.62 | +57.14% | Beat | N/A | 10 | 0 up, 0 down | Feb 24, 2022 | $55.60M |
| Sep 30, 2021 | -$0.95 | -$0.77 | -$0.93 - -$0.69 | -23.38% | Miss | N/A | 8 | N/A | Nov 3, 2021 | $5.44M |
| Jun 30, 2021 | -$0.86 | -$0.66 | -$0.70 - -$0.58 | -30.30% | Miss | N/A | 9 | N/A | Aug 5, 2021 | $2.84M |
| Mar 31, 2021 | -$0.66 | -$0.60 | -$0.68 - -$0.48 | -10.00% | Miss | N/A | 8 | N/A | May 6, 2021 | $6.55M |
| Dec 31, 2020 | -$0.62 | -$0.30 | -$0.60 - $0.63 | -106.67% | Miss | N/A | 8 | N/A | Feb 25, 2021 | $6.72M |
| Sep 30, 2020 | -$0.05 | -$0.34 | -$0.64 - $1.26 | +85.29% | Beat | N/A | 8 | N/A | Nov 4, 2020 | $41.69M |
| Jun 30, 2020 | -$0.68 | -$0.57 | -$0.61 - -$0.46 | -19.30% | Miss | N/A | 7 | N/A | Aug 6, 2020 | $3.59M |
| Mar 31, 2020 | -$0.66 | -$0.50 | -$0.55 - -$0.43 | -32.00% | Miss | N/A | 6 | N/A | May 6, 2020 | $3.83M |
| Dec 31, 2019 | -$0.52 | -$0.44 | -$0.54 - -$0.26 | -18.18% | Miss | N/A | 6 | N/A | Mar 3, 2020 | $5.21M |
| Sep 30, 2019 | -$0.50 | -$0.49 | -$0.57 - -$0.35 | -2.04% | Miss | N/A | 5 | N/A | Oct 31, 2019 | $6.05M |
| Jun 30, 2019 | -$0.56 | -$0.50 | -$0.56 - -$0.44 | -12.00% | Miss | N/A | 5 | N/A | Aug 8, 2019 | $7.14M |
| Mar 31, 2019 | -$0.54 | -$0.47 | -$0.50 - -$0.44 | -14.89% | Miss | N/A | 5 | N/A | May 9, 2019 | $8.46M |
| Dec 31, 2018 | -$0.48 | -$0.52 | -$0.58 - -$0.44 | +7.69% | Beat | N/A | 5 | N/A | Feb 21, 2019 | $9.38M |
| Sep 30, 2018 | -$0.40 | -$0.52 | -$0.56 - -$0.45 | +23.08% | Beat | N/A | 5 | N/A | Nov 1, 2018 | $10.64M |
| Jun 30, 2018 | -$0.51 | -$0.51 | -$0.55 - -$0.46 | 0.00% | In line | N/A | 5 | N/A | Jul 26, 2018 | $6.21M |
| Mar 31, 2018 | -$0.56 | -$0.58 | -$0.61 - -$0.18 | +3.45% | Beat | N/A | 6 | N/A | Apr 26, 2018 | $5.27M |
| Dec 31, 2017 | -$0.75 | -$0.70 | -$0.93 - -$0.38 | -7.14% | Miss | -568.8% | 7 | N/A | Feb 15, 2018 | N/A |
| Sep 30, 2017 | -$0.60 | -$0.62 | -$0.81 - -$0.39 | +3.23% | Beat | -181.1% | 7 | N/A | Oct 26, 2017 | $6.18M |
| Jun 30, 2017 | -$0.60 | -$0.60 | -$0.74 - -$0.19 | 0.00% | In line | N/A | 6 | N/A | Aug 2, 2017 | $3.05M |
| Mar 31, 2017 | -$0.62 | -$0.61 | N/A | -1.64% | Miss | N/A | N/A | N/A | Apr 27, 2017 | $4.15M |
| Dec 31, 2016 | $0.16 | -$0.26 | N/A | +161.54% | Beat | N/A | N/A | N/A | Feb 16, 2017 | $33.14M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.52, after -$5.26 the year before. It was $0.30 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.52 | N/A |
| Dec 31, 2024 | -$5.26 | N/A |
| Dec 31, 2023 | -$5.45 | N/A |
| Dec 31, 2022 | -$3.98 | N/A |
| Dec 31, 2021 | -$2.83 | N/A |
| Dec 31, 2020 | -$2.01 | N/A |
| Dec 31, 2019 | -$2.12 | N/A |
| Dec 31, 2018 | -$1.95 | N/A |
| Dec 31, 2017 | -$2.57 | -956.7% |
| Dec 31, 2016 | $0.30 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,100 words across 25 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,083 | 25 | |
| 2026Q2 | Jun 30, 2026 | 9,731 | 26 | |
| 2026Q1 | Mar 31, 2026 | 3,860 | 7 | |
| 2025Q4 | Dec 31, 2025 | 7,298 | 16 | |
| 2025Q3 | Sep 30, 2025 | 7,708 | 24 | |
| 2025Q2 | Jun 30, 2025 | 9,896 | 21 | |
| 2025Q1 | Mar 31, 2025 | 9,920 | 29 | |
| 2024Q4 | Dec 31, 2024 | 9,457 | 25 |
2026Q3 Earnings Call
Opening remarks
Diane Weiser Senior Vice President of Corporate Affairs Good afternoon, and thanks for joining us on the call today. The slides accompanying today's webcast can be found on the Investors and Media section of our website at cytokinetics.com, along with today's press release. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of MYQORZO in the U.S. and Europe. Fady Malik, EVP of R&D, will provide updates related to aficamten. Steve Heitner, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sung Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter. Finally, Robert will make closing remarks. As you can see on this slide, today's discussion will include forward-looking statements, which are subject to risks and uncertainties. Please refer to our SEC filings for a discussion of these factors. And now I will turn the call over to Robert.
Robert I. Blum President and Chief Executive Officer Thank you, Diane. And thanks to all for joining us on the call today. The third quarter was another period of strong execution for Cytokinetics as we continue to build a leading muscle-focused specialty cardiology company. In Q3, we made progress on each of our priorities underlying that strategy. Nearly nine months in, the launch of MYQORZO continues to exceed our expectations. In the third quarter, MYQORZO generated $44.5 million in net revenue, up 76% from Q2. As Andrew will describe, the number of prescribers prescribing per physician and patients dispensed all increased. We believe these trends reflect the differentiated profile of MYQORZO, and we see significant room for continued growth. Outside the United States, our launch in Germany is off to a strong start, and we continue to secure approvals in additional geographies, including recently in Canada and the United Kingdom. We expect to launch in the U.K. this quarter and in additional countries in 2027. We're also looking forward to the PDUFA date for data relating to MAPLE-HCM, which is November 14. Beyond oHCM, we're working diligently to bring aficamten to more patients living with HCM. In August, we presented the full results from ACACIA-HCM in a hotline session at ESC with simultaneous publication in the New England Journal of Medicine. In fact, the presentation was included in the opening plenary session for ESC, a clear sign of enthusiasm from the cardiology community, which today has no approved therapy that addresses the underlying disease for nHCM. We also presented additional results at ESC from prespecified analyses from ACACIA-HCM that further underscore the potential of aficamten in nHCM.
Frequently Asked Questions About CYTK
When is Cytokinetics's next earnings date?
Cytokinetics's next earnings report is expected for Feb 22, 2027.
Did CYTK beat earnings estimates last quarter?
Yes. Cytokinetics reported EPS of -$1.37 for the quarter ended Sep 30, 2026, above the -$1.50 estimate, a 8.67% surprise.
What EPS do analysts expect from CYTK next quarter?
The consensus EPS estimate for Cytokinetics for the quarter ending Dec 31, 2026 is -$1.44 from 24 analysts, with estimates from -$1.58 to -$0.98.
How often does CYTK beat earnings estimates?
Cytokinetics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.94%.
CYTK pages: Overview, Earnings, Forecast, Financials, Competitors